All In Biotech

Drug Trial Radar · NCT00870740

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis

A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)

Last checked: Nov 20, 2026Latest source record: Aug 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 517 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

517

Actual

Start

Feb 2009

Primary completion

May 2012

Study completion Oct 2012

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
AbbVie
First posted
Mar 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to assess the safety and immunogenicity of extended treatment with DAC HYP. This evaluation included the following major components: * An assessment of safety and immunogenicity of extended treatment with DAC HYP when administered to MS subjects who had completed 52 weeks of active therapy with DAC HYP in Study 201. * An assessment of safety and immunogenicity during a 6-month washout period from DAC HYP. * An assessment of safety and immunogenicity during reinitiation of therapy with DAC HYP after a 6-month washout period. * An assessment of safety and immunogenicity of DAC HYP when administered to MS subjects who previously received placebo during Study 201. The secondary objective is to assess the durability of the effect of DAC HYP on multiple sclerosis (MS) disease activity as measured by brain magnetic resonance imaging (MRI) scans and clinical MS relapses.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

  • BIIB019 (Daclizumab High Yield Process)Biological

    SC injection

  • PlaceboDrug

    Placebo SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (AEs)Time frame: Up to 72 weeks
  2. Number of Participants With Abnormalities in Vital SignsTime frame: Up to Week 72
  3. Number of Participants With Potentially Clinically Significant Hematology Laboratory AbnormalitiesTime frame: Up to 72 Weeks
  4. Number of Participants With Abnormalities in Blood Chemistry Laboratory DataTime frame: Up to 72 Weeks
  5. Number of Participants With Development of Anti-DAC Antibodies (ADAb) and Neutralizing Antibodies (NAb) Post-baselineTime frame: Up to 72 weeks

Locations

58 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Brno, Czechia

  • Research Site

    Hraddec Kralove, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Pilsen, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Teplice, Czechia

  • Research Site

    Bayreuth, Germany

  • Research Site

    Erlangen, Germany

  • Research Site

    Marburg, Germany

  • Research Site

    Osnabrück, Germany

  • Research Site

    Regensburg, Germany

  • Research Site

    Rostock, Germany

  • Research Site

    Budapest, Hungary

  • Research Site

    Debrecen, Hungary

  • Research Site

    Esztergom, Hungary

  • Research Site

    Győr, Hungary

  • Research Site

    Kecskemét, Hungary

  • Research Site

    Miskolc, Hungary

  • Research Site

    Nyíregyháza, Hungary

  • Research Site

    Siófok, Hungary

  • Research Site

    Zalaegerszeg, Hungary

  • Research Site

    Andra-Pradeash, India

  • Research Site

    Bangalore, India

  • Research Site

    Jaipur, India

  • Research Site

    Kolkata, India

  • Research Site

    Mumbai, India

  • Research Site

    Visakhapatnam, India

  • Research Site

    Bialystok, Poland

  • Research Site

    Gdansk, Poland

  • Research Site

    Katowice, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Lodz, Poland

  • Research Site

    Lublin, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Kazan', Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Omsk, Russia

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.